FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of February 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [ X ] Form 40 - F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [ X ]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on February 15, 2000, titled:
"Vasogen Appoints Prominent Harvard Immunologist to Scientific Advisory Board"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/Christopher Waddick
----------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: February 15, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive, Suite 10 Trevor Burns
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel (905) 569-2265 fax (905) 569-9231 tel (905) 569-9065
http://www.vasogen.com e-mail [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN APPOINTS PROMINENT HARVARD IMMUNOLOGIST
TO SCIENTIFIC ADVISORY BOARD
Toronto, Ontario (February 15, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) is
pleased to announce the appointment of prominent Harvard immunologist Dr. Fred
S. Rosen to its Scientific Advisory Board. Dr. Rosen is President of the Center
for Blood Research in Boston and Professor of Pediatrics at Harvard Medical
School.
Dr. Rosen is internationally recognized for his groundbreaking research into the
functioning of the immune system and the causes of immune deficiency diseases.
His wide scientific leadership in immunology has led to fundamental insights
into the mechanisms by which immune responses are initiated. His work has been
widely published in premier scientific journals, such as Science, Nature, The
Lancet, and The New England Journal of Medicine, where his immunology review
articles are considered classics.
Dr. Rosen has received wide international recognition as a leader in his field.
He has been elected as an honorary member to scientific societies in many
countries, including becoming a Membre d'Honneur for Life of the French Society
of Immunology, and is the recipient of numerous honorary degrees and honours,
including being a Distinguished Visiting Scholar at Christ's College, Cambridge
University, England. Dr. Rosen is also active in several important committees
and scientific societies and currently chairs the Scientific Advisory Committee
of the Clinical Research Center, Children's Hospital, Boston and the World
Health Organization's Expert Scientific Committee on Immunodeficiency.
"To attract an individual of the calibre of Dr. Rosen to Vasogen's Scientific
Advisory Board is a major achievement for our Company," said Dr. Eldon Smith,
Vasogen's Vice-President, Scientific Affairs. "He brings major strength to our
immunology expertise at a time when it is becoming increasingly apparent that an
enhanced understanding of the immune mechanisms underlying Vasogen's immune
modulation therapies will accelerate the continued advancement of our products."
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
